One-off gene-editing therapy could permanently lower cholesterol

Single-Dose Gene Editing Therapy Shows Promise in Lowering Cholesterol

A groundbreaking study indicates that a single-administration treatment to decrease the lifelong risk of heart disease is moving closer to reality. In a preliminary clinical trial, a solitary dose of a CRISPR-based gene-editing therapy successfully reduced cholesterol levels in patients, with no serious adverse effects reported.

Heart-2 Trial Details

The “Heart-2” trial, conducted by Verve Therapeutics, a biotechnology company based in Boston, enrolled 14 individuals. Participants included those with an inherited disorder causing abnormally high cholesterol and individuals who had developed heart disease at a young age. This research represents an early phase of investigation into this novel therapeutic approach.

🕐 Top News in the Last Hour By Importance Score

#	Title	📊 i-Score
1	Suspect in custody after 4 hurt in Texas high school shooting	🔴 75 / 100
2	North Korea’s sacred Mount Paektu designated as UNESCO Global Geopark	🔴 75 / 100
3	Protester tasered and arrested at Republican town hall	🔴 72 / 100
4	Judge rejects defense that Gaudreau brothers contributed to own deaths	🔴 72 / 100
5	Houses sell the fastest in these ten regions in England and Wales – check your area	🔴 65 / 100
6	Major airlines issue statements over cancelled holidays amid Lanzarote flooding	🔵 55 / 100
7	New photos from European Mars orbiter show dynamic, volcanic Red Planet terrain	🔵 35 / 100
8	Bethesda Is Selling 2,000 Pieces Of Elder Scrolls Online's Servers	🔵 32 / 100
9	Michael Schumacher 'made helicopter journey' for major family event as new details emerge	🔵 30 / 100
10	Buh-Bye, Body Hair: An Esthetician’s Guide To At-Home Hair Removal	🟠 5 / 100

View More Top News ➡️